Kaisa Huhtinen
PhD, Adjunct Professor in Cancer Biology
kaisa.huhtinen@utu.fi +358 29 450 2645 +358 50 572 6733 Kiinamyllynkatu 10 Turku Office: D5038 ORCID identifier: https://orcid.org/0000-0001-9685-5246 |
Areas of expertise
Ovarian cancer; personalized medicine; early diagnostics; prediction; prognosis; biomarker; genomics; drug target; interdicipline research;
Ovarian cancer; personalized medicine; early diagnostics; prediction; prognosis; biomarker; genomics; drug target; interdicipline research;
Biography
Research
Publications
- Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer (2026)
- Cancer ResearchClinica Chimica Acta
(A1 Refereed original research article in a scientific journal) - MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancerA platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids (2025)
- Scientific Reports
- Novel glycovariant biomarkers of CA125 and CA15-3 and their diagnostic performance across histotypes of ovarian cancer: A multi-cohort study in Sweden and Finland (2025)
- European Journal of Obstetrics and Gynecology and Reproductive Biology
(A1 Refereed original research article in a scientific journal) - Deciphering cancer genomes with GenomeSpy : a grammar-based visualization toolkit (2024)
- GigaScience
(A1 Refereed original research article in a scientific journal) - Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma (2024)
- BMC Cancer
(A1 Refereed original research article in a scientific journal) - HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma (2024)
- Gynecologic Oncology
(A1 Refereed original research article in a scientific journal) - Locus-specific LINE-1 expression in clinical ovarian cancer specimens at the single-cell level (2024)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures (2024)
- Neoplasia
(A1 Refereed original research article in a scientific journal) - Aberrant glycosylation of α3 integrins as diagnostic markers in epithelial ovarian cancer (2023)
(A1 Refereed original research article in a scientific journal) - (2023)
- Developmental Cell
(A1 Refereed original research article in a scientific journal)



